pharmaceutical investing Coherus BioSciences Announces Positive Topline 24-Week Treatment Phase Three Results for CHS-1420 (HUMIRA® Biosimilar Candidate) in Patients with Psoriasis
Cellceutix Reports 24 Core Phase 2b Clinical Trial Sites for Oral Prurisol Treatment of Moderate-To-Severe Psoriasis
UCB and Dermira Announce Second CIMZIA® Phase 3 Trial Meets Co-Primary Efficacy Endpoints in Patients with Moderate-to-Severe Chronic Plaque Psoriasis
Momenta Pharmaceuticals Announces Positive Top-Line Phase 3 Results for M923, a Proposed HUMIRA® Biosimilar
CIMZIA® Phase 3 Trial Meets Co-primary Efficacy Endpoints in Patients with Moderate-to-Severe Chronic Plaque Psoriasis
Exicure Announces Dosing of First Patient in Phase 1 Trial for the Treatment of Chronic Plaque Psoriasis
Goldgroup Enters Into Agreement To Sell Subsidiary Minera Apolo, S.A. de C.V., Disposing of Pinos Project
55 North Mining Appoints Wayne Parsons as Executive Chair; Strengthens Leadership as the Company Advances the Last Hope Gold Project
